Sign in
Not yet taking people in Hong KongPhase 4

Maraviroc for myositis that has not responded to usual treatments

Tests maraviroc in adults whose myositis did not improve with usual treatments.

Key facts

Who runs it
Chinese University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies
Status
Not yet recruiting
Phase
Phase 4
People taking part
10 people, planned
Started
1 Sept 2026
Expected to end
31 Aug 2029
Type of study
Interventional
Treatments tested
  • maraviroc (Selzentry, Celsentri)
Record updated
30 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active inflammatory muscle disease (myositis) that has not improved with earlier treatments. All participants take Maraviroc 300mg daily for 12 weeks.

Age
18 to under 80 years. The myositis must have started after age 18.
Sex
All sexes can join.
Disease stage
Idiopathic inflammatory myopathy that meets the 2017 ACR/EULAR criteria. The disease must be active: MMT8 muscle strength score below 142, plus at least two other abnormal measures. These can be patient or doctor activity score of at least 2 cm (0.8 in), a muscle enzyme above 1.5 times the upper normal limit, or HAQ score of at least 0.25.
Earlier treatment
The disease must still be active despite glucocorticoids (steroids) plus 2 other immune-suppressing treatments.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Cancer
  • Functional class 4 (most severe physical limitation)
  • Any medical reason not to take Maraviroc

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • ≥18 to <80 years of age
  • Myositis disease onset >18 years
  • Fulfillment of 2017 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) IIM classification criteria
  • Active myositis defined as Manual Muscle Testing 8 (MMT8) score <142 with at least two other abnormal International Myositis Assessment \& Clinical Studies Group (IMACS) core set measures (Visual Analogue Scale (VAS) of patient global activity ≥2 cm, physician's global disease activity ≥2 cm, at least one muscle enzyme >1.5 times upper limit of normal, Health ssessment Questionnaire(HAQ) ≥0.25), despite 2 additional immunosuppressive treatments on top of glucocorticoids

Who cannot take part

  • Malignancy
  • Pregnancy or lactation,
  • Functional class 4
  • Contraindication to Maraviroc

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in Hong Kong

  • Prince of Wales HospitalHong Kong, Hong KongContact: Huating Wang, Ph.dNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if the drug Maraviroc works to treat refractory idiopathic inflammatory myopathy (myositis) in patients who have not responded well to traditional therapies. It will also learn about how the drug affects muscle inflammation and function. The main questions it aims to answer are: Does Maraviroc reduce inflammation in the muscles? Does Maraviroc improve patients' muscle function and overall clinical symptoms? This is an open-label study, meaning researchers will give Maraviroc to all participants (there is no placebo) to see if the drug works to treat refractory myositis. Participants will: Take a 300mg Maraviroc tablet every day for 12 weeks. Undergo exams and tests with their doctors to check their muscle function, symptom improvement, and specific health markers (like enzyme levels).

The group in the trial

  • Maraviroc groupTreatment being tested

    Treatment: maraviroc (Selzentry, Celsentri)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies
Plain-language title
Maraviroc for myositis that has not responded to usual treatmentsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07668505, who can take part
Record updated
30 June 2026